LipoNova Got General Approval from FDA for The Overall Development Program of The Autologous Tumor Vaccine in Renal Cancer

The US registration authority FDA shows LipoNova the way to the US market for its first product candidate Reniale(R)

(PresseBox) ( Hannover, )
LipoNova AG (WKN LNAG00) the pioneering developer of Reniale(R), the world’s first autologous vaccine for renal cell carcinoma (RCC) has been given the go-ahead by the FDA for its overall development program. The Pre-IND meeting has been the first milestone for LipoNova towards the approval of the new international phase III study.

Dr. Cornelius Sobel, Chief Executive Officer said: "We are delighted with the outcome of this meeting. Today marks a significant step towards Reniale(R) becoming available as the first ever autologous tumor vaccine for patients who have renal cell carcinoma.

The approved program allows us to move to an international phase III trial, which demonstrates that our well-designed process meets the expectations of the agency. The FDA encouraged us to submit the IND for the phase III study which we plan to start in the first half of 2008.”

Reniale(R) has previously been tested in a phase-III clinical study on adjuvant therapy of renal cell carcinoma in Germany which demonstrated positive therapeutic results with improved disease free and also overall survival rates while maintaining the quality of life.

At present, no approved adjuvant treatment exists for patients suffering from renal cell carcinoma after surgical removal of the tumor. There is an urgent need for a new medical treatment for this unmet medical need. Reniale(R) would be the first autologous tumor vaccine anywhere in the world with no other comparable therapy on the market.

In Europe and the USA about 100 thousand patients are diagnosed each year with RCC and the majority of them receive surgery to have the tumor removed and would then be candidates for the adjuvant treatment with Reniale(R). The revenues from a 40% take up of Reniale(R) by this patient population would be worth 1 billion Euros per year. The new study is expected to include 800 patients and recruitment may last approximately 24 months. The cost of the study is expected to range between 25-30 million Euros.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to